High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia
- 259 Downloads
Patients with acute lymphoblastic leukemia presenting the immunophenotypic marker CD10+ (calla), usually has treatment profile good. The FLT3 molecular marker is listed as a prognostic factor, an important leukaemogenic marker in acute leukemias, also the polymorphism (G1082A) of the IL10 interleukin can to present pleiotropic effects in many diseases and could is associated to development of ALL. However, the FLT3 expression is variability among patients with calla-ALL. The aim of this study was to determine the FLT3 expression, to associate with the genotypes and allelic of G1082A (IL10) in 50 patients with calla-ALL and assess the overall survival at 98 months follow-up. The expression was assessed by quantitative real time PCR (RT-PCR), the G1082A polymorphism was identified by allele-specific PCR and for immunophenotypic classification was used specific markers of B lineage-calla. We observed that patients who died showed higher FLT3 expression (p = 0.005), worse survival (p = 0.0137) and the IL10G allele may favor the survival, because the IL10 GG and IL10 GA genotypes showed a low FLT3 expression (p < 0.05).
KeywordsCalla ALL FLT3 expression Overall survival IL10 (G1082A) polymorphism
We thank the FACEPE (Foundation for assistance to science and technology of the state of Pernambuco), UNIPECLIN (Clinical Research Unit) and CAPES (Coordination for Improvement in Higher Education). We thank the support of Dr. Ednalva Pereira Leite (CEONHPE) and Dr. Vera Lúcia Lins de Morais (CEONHPE) for clinical competence.
- 3.Mari B, Auberger P (1995) Structure et fonction des ectopeptidases du système immunitaire. Med Sci 11:681–690Google Scholar
- 24.Cazé MO, Bueno D, Santos ME (2010) Referential study of a chemotherapy protocol for acute lymphocytic leukemia in childhood. Rev HCPA 30(1):5–12Google Scholar
- 31.Byrd JC, Mrózek K, Dodge RK et al (2012) Success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia, Group B (CALGB 8461). Blood 100(13):4325–4336CrossRefGoogle Scholar
- 32.Slovak ML, Kopecky KJ, Cassileth PA et al (2012) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96(13):4075–4083Google Scholar